(Q41592949)

English

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer

scientific article published on 16 May 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 October 2017

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer (English)

1 reference

Europe PubMed Central

4 October 2017

1 reference

based on heuristic

inferred from title

19

object named as

Bohua Li

1 reference

Europe PubMed Central

4 October 2017

16

object named as

Hao Wang

1 reference

Europe PubMed Central

4 October 2017

12

object named as

Huajing Wang

1 reference

Europe PubMed Central

4 October 2017

14

object named as

Huafeng Wei

1 reference

Europe PubMed Central

4 October 2017

8

object named as

Yanchun Meng

1 reference

Europe PubMed Central

4 October 2017

author name string

Lingfei Wang

1

1 reference

Europe PubMed Central

4 October 2017

Xiaojie Yu

2

1 reference

Europe PubMed Central

4 October 2017

Chao Wang

3

1 reference

Europe PubMed Central

4 October 2017

Shujun Pan

4

1 reference

Europe PubMed Central

4 October 2017

Beibei Liang

5

1 reference

Europe PubMed Central

4 October 2017

Yajun Zhang

6

1 reference

Europe PubMed Central

4 October 2017

Xiaodan Chong

7

1 reference

Europe PubMed Central

4 October 2017

Jian Dong

9

1 reference

Europe PubMed Central

4 October 2017

Yirong Zhao

10

1 reference

Europe PubMed Central

4 October 2017

Yang Yang

11

1 reference

Europe PubMed Central

4 October 2017

Jie Gao

13

1 reference

Europe PubMed Central

4 October 2017

Jian Zhao

15

1 reference

Europe PubMed Central

4 October 2017

Chaohua Hu

17

1 reference

Europe PubMed Central

4 October 2017

Wenze Xiao

18

1 reference

Europe PubMed Central

4 October 2017

language of work or name

0 references

publication date

16 May 2017

1 reference

Europe PubMed Central

4 October 2017

1 reference

Europe PubMed Central

4 October 2017

8

1 reference

Europe PubMed Central

4 October 2017

32

1 reference

Europe PubMed Central

4 October 2017

52877-52888

1 reference

Europe PubMed Central

4 October 2017

An anti-ErbB2 fully human antibody circumvents trastuzumab resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Live to die another way: modes of programmed cell death and the signals emanating from dying cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Programmed necrosis and necroptosis signalling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Necroptosis: an emerging form of programmed cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Granulysin induces cathepsin B release from lysosomes of target tumor cells to attack mitochondria through processing of bid leading to Necroptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Unraveling the microenvironmental influences on the normal mammary gland and breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Src family kinases: regulation of their activities, levels and identification of new pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

6 June 2018

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

19 August 2018

Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

19 August 2018

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5581078

19 August 2018

SnapShot: breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28881779

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2/neu amplification in breast cancer: stratification by tumor type and grade

1 reference

https://pubmed.ncbi.nlm.nih.gov/28881779

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.18632/ONCOTARGET.17907

1 reference

Europe PubMed Central

4 October 2017

1 reference

Europe PubMed Central

4 October 2017

1 reference

Europe PubMed Central

4 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41592949&oldid=1924811571"